Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Our lead programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. Our medicinal chemistry, virology, and pharmacology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our purine nucleotide prodrug platform, our goal is to rapidly advance novel drug candidates with optimal therapeutic profiles for RNA virus targets. Founded by its Chairman and Chief Executive Officer, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is headquartered in Boston, MA. *

 

Period Start 2014-01-01 start
Products Industry virostatic agent
  Industry 2 drug development
     
Region Region Boston, MA
  Country United States (USA)
  Street 125 Summer Street
  City 02110 Boston, MA
  Tel +1-857-284-8891
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Atea Pharmaceuticals, Inc.. (10/22/20). "Press Release: Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19". Boston, MA.
     
   
Record changed: 2020-10-26

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Atea Pharmaceuticals Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top